



POWERED BY COR2ED

# KRAS MUTANT COLORECTAL CANCER: THE NOW AND THE NEXT

Dr. Shubham Pant, MD Anderson Cancer Center  
Houston, Texas, USA

# INTRODUCTION

- KRAS mutation can occur in approximately 40% of cases of colorectal cancer
- Patients with mutations in KRAS are not candidates for therapy with anti-EGFR directed therapy with cetuximab and panitumumab

# CHALLENGES IN TARGETTING K-RAS

- RAS has been regarded as ‘undruggable’ for many years
- One of the reasons is that RAS proteins do not appear to have a binding pocket as they bind very tightly to the GDP-GTP binding site

# NEWER AGENTS

- Newer agents are attempting to target the downstream targets especially the ERK pathway
- There are agents in early phase drug development that are targeting this pathway

# NEWER AGENTS

- There is renewed interest to target KRAS with directed siRNA therapy
- In addition combination of MEK inhibitors and PD-1 antibodies are being combined in patients with colorectal cancers



GI CONNECT  
Bodenackerstrasse 17  
4103 Bottmingen  
SWITZERLAND

Dr. Antoine Lacombe  
Pharm D, MBA  
Phone: +41 79 529 42 79  
[antoine.lacombe@cor2ed.com](mailto:antoine.lacombe@cor2ed.com)

Dr. Froukje Sosef  
MD  
Phone: +31 6 2324 3636  
[froukje.sosef@cor2ed.com](mailto:froukje.sosef@cor2ed.com)

